Key Highlights

  • The third-quarter net loss came to USD 8.9 million, or USD 0.26 per share, against USD 7.4 million, or USD 0.60 per share, a year ago, when the share base was far smaller.
  • Cash and cash equivalents climbed to USD 289.6 million at September 30, 2026, from USD 48.3 million at December 31, 2025, following two Equity raises.
  • Operating expenses increased to USD 10.7 million from USD 7.6 million, split between Research and Development at USD 5.1 million and general and administrative costs at USD 5.5 million.
  • Week 36 results showed a mean SALT score reduction of 35.3%, and a registration-directed bempikibart program is slated to begin in the first half of 2027.

Quarterly Loss Grows in Dollars but Shrinks Per Share

Q32 Bio (NASDAQ:QTTB) is a clinical-stage biotechnology company centered on alopecia areata and other autoimmune and inflammatory conditions. It filed its Quarterly Report for the period ended September 30, 2026 on November 4, 2026. The net loss widened to USD 8.9 million from USD 7.4 million, yet the loss per share narrowed to USD 0.26 from USD 0.60, because weighted shares climbed to 34.0 million from 12.2 million. Research and development outlays rose to USD 5.1 million from USD 3.6 million, mainly reflecting higher bempikibart Manufacturing and clinical spending. Other income increased to USD 1.7 million from USD 0.2 million on larger average cash balances.

Financing Pulls the Balance Sheet Back Up

Financing accounts for the rebuilt cash position. A private Placement on May 28, 2026 issued 6,725,000 shares at USD 8.00, producing net proceeds of USD 53.4 million. A public offering on July 16, 2026 sold 6,027,399 shares at USD 18.25 along with pre-funded warrants, generating USD 187.5 million net. Shares outstanding stood at 29,892,127 at quarter end against 12,858,047 on December 31, 2025, which dilutes existing holders. The accumulated Deficit was USD 230.5 million and stockholders' equity was USD 287.7 million at quarter end. On June 24, 2026, the company repaid its remaining venture Debt of about USD 6.8 million, and it also has an at-the-market sales agreement in place.

Bempikibart Response Rates and the Registration Timeline

In SIGNAL-AA Part B, 40.0% of 25 patients in the modified analysis, and 30.3% of all 33 enrolled, reached a SALT-20 response at Week 36. Among 18 patients in the off-drug follow-up, 44% achieved a SALT-20 response at 16 weeks. Bempikibart has been given to more than 150 participants across all trials without any Grade 3 or higher treatment-related adverse events. Regulatory discussions are planned for the fourth quarter of 2026, with a registration-directed program targeted for the first half of 2027. Management expects its cash to carry operations through topline Phase 3 results for bempikibart, though not through approval. Q32 Bio (NASDAQ:QTTB) will still need more capital, and trial outcomes remain uncertain.

Where Things Stand

On the company's own estimate, yes for the next stage, but not beyond it. Q32 Bio (NASDAQ:QTTB) says its USD 289.6 million of cash should cover operations through topline Phase 3 results for bempikibart, and it does not expect that cash to carry the program through regulatory approval. The near-term markers are fourth-quarter regulatory discussions, the first-half 2027 program start and open-label extension results expected in the second half of 2027.